• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fluidigm Corporation

    3/24/22 4:30:36 PM ET
    $FLDM
    Biotechnology: Laboratory Analytical Instruments
    Capital Goods
    Get the next $FLDM alert in real time by email
    SC 13G 1 tm2210375d1_sc13g.htm SC 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

     

    FLUIDIGM CORP.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    34385P108

    (CUSIP Number)

     

               March 14, 2022           

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 34385P108

     

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ¨

    (b)  ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,651,177

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,651,177

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,651,177

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

           

     

     

     

    CUSIP No. 34385P108

     

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ¨

    (b)  ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,651,177

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,651,177

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,651,177

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

    CUSIP No. 34385P108

     

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ¨

    (b)  ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,651,177

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,651,177

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,651,177

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

           

     

     

     

    CUSIP No. 34385P108

     

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ¨

    (b)  ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,651,177

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,651,177

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,651,177

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

           

     

     

     

     

    Item 1(a).Name of Issuer:

     

    Fluidigm Corp. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    2 Tower Place, Suite 2000, South San Francisco, CA 94080

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital is a Delaware limited partnership. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.001 par value per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    34385P108

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 77,198,577 total Common Stock shares, as reported in the Issuer’s Prospectus filed with the Securities and Exchange Commission on March 8, 2022.

     

    The Fund directly holds 4,651,177 shares of Common Stock.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolios, including the shares of the Issuer’s Common Stock reported herein.  Because the Fund has divested itself of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1: Joint filing agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: March 24, 2022

     

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Authorized Signatory

     

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky

     

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah

     

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC
    Its:General Partner

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Manager

     

     

     

    EXHIBIT 1

     

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of March 24, 2022, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock $0.001 per share of Fluidigm Corp. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Authorized Signatory

     

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky

     

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah

     

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By:RA Capital Healthcare Fund GP, LLC
    Its:General Partner

     

    By:/s/ Peter Kolchinsky
    Name:Peter Kolchinsky
    Title:Manager

     

     

    Get the next $FLDM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FLDM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (NASDAQ:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm, the Company's new President, Chief Executive Officer and a member of the Company's Board of Directors, and Hanjoon (Alex) Kim, the Company's new Chief Operating Officer, and a new employee, Ardalan (Alex) Arfaei, the Company's new Senior Vice President, Corporate Development. In accordance with Nasdaq Listing Rule 5635(c)(4), Standard BioTools' Compensation Committee of its Board of Directors, which is composed entirely

      4/5/22 7:15:24 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

      SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Dr. Carlos V. Paya, chairman of Fluidigm, said, "On behalf of the Board of Directors, I would like to thank our stockholders for their support of this investment, which is expected to fuel a realization of identified growth and cost opportunities within the Company's two major platforms, mass cytometry and microfluidics, and pave the way

      4/1/22 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:11:15 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:06:21 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:05:59 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Fluidigm with a new price target

      Piper Sandler reiterated coverage of Fluidigm with a rating of and set a new price target of $8.00 from $15.00 previously

      2/11/21 12:35:14 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    SEC Filings

    See more
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      7/7/22 4:00:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/27/22 4:04:35 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/16/22 2:06:26 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Financials

    Live finance-specific insights

    See more
    • Fluidigm Announces Third Quarter 2021 Financial Results

      Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the third quarter ended September 30, 2021. "We saw a very active third quarter and made progress with our ambitious plan to commercially scale two new instrument systems," said Chris Linthwaite, President and CEO. "Core demand for our products was healthy, but we were unable to fulfill all orders for our products during the quarter, largely due to supply chain issues. Our b

      11/8/21 4:02:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

      SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 8, 2021, to discuss third quarter 2021 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals int

      10/20/21 8:30:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million

      Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the second quarter ended June 30, 2021. "Second quarter results were driven by a rebound in our base business and early customer orders following the launch of our new fourth generation CyTOF® XT mass cytometry product," said Chris Linthwaite, President and CEO. "Our services busines

      8/5/21 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

      Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm's current largest holder of common stock, under which Caligan has agreed to vote "FOR" all Fluidigm proposals related to the

      3/29/22 9:29:06 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem in South San Francisco and appointed Gajus Worthington to its Board of Directors. The Company is now positioned to accelerate the translation of its proprietary cf-mRNA Liquid Biopsy Technology Platform to develop products and services for Precision Medicine clinical practice and biopharma R&D. "We

      1/4/22 6:00:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      6/7/22 10:31:54 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      5/3/22 12:40:48 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13G filed by Fluidigm Corporation

      SC 13G - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      4/14/22 5:09:34 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods